Shubin Qiao1, Lianglong Chen2, Shao-Liang Chen3, Weimin Wang4, Beth Ferri5, Minglei Liu5, Guoying Zhu6. 1. Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China. 2. Department of Cardiology, Union Hospital, Fujian Medical University, Fujian, China. 3. Department of Cardiology, Nanjing First Hospital, Jiangshu, China. 4. Department of Cardiology, Peking University People's Hospital, Beijing, China. 5. Division of Coronary and Structural Heart, Medtronic PLC, Santa Rosa, CA, USA. 6. Department of Cardiology, Wuhan Asia Heart Hospital, Hubei, China.
Abstract
AIMS: Long-term clinical outcome data for second-generation drug-eluting stents (DES) are critical for the assessment of safety and efficacy. Five-year results from the RESOLUTE China Registry are presented in this report. METHODS AND RESULTS: The RESOLUTE China Registry is a prospective, multicentre, observational study for all-comers requiring coronary stent implantation. The primary endpoint was target lesion failure (TLF) at one year, and the main secondary endpoint was definite or probable stent thrombosis at one year. Additional secondary endpoints assessed up to 5 years include rates of all deaths, target vessel myocardial infarction (TVMI) and target lesion revascularisation (TLR). A total of 1,800 patients were enrolled from December 2010 to March 2012 at 30 sites in China and implanted with Resolute DES. At 5 years, TLF was 9.8%, TVMI 3.2%, TLR 4.6% and very late stent thrombosis 0.5%. Results of pre-specified subgroup analyses show 5-year TLF rates of 14.3% for diabetics and 13.4% for patients with chronic total occlusions. CONCLUSIONS: The RESOLUTE China Registry is the largest study of Asian patients treated with second-generation Resolute DES. Clinical outcomes illustrate a robust safety and efficacy profile of Resolute DES in a real-word Asian population, including favourable performance in complex patient subsets.
AIMS: Long-term clinical outcome data for second-generation drug-eluting stents (DES) are critical for the assessment of safety and efficacy. Five-year results from the RESOLUTE China Registry are presented in this report. METHODS AND RESULTS: The RESOLUTE China Registry is a prospective, multicentre, observational study for all-comers requiring coronary stent implantation. The primary endpoint was target lesion failure (TLF) at one year, and the main secondary endpoint was definite or probable stent thrombosis at one year. Additional secondary endpoints assessed up to 5 years include rates of all deaths, target vessel myocardial infarction (TVMI) and target lesion revascularisation (TLR). A total of 1,800 patients were enrolled from December 2010 to March 2012 at 30 sites in China and implanted with Resolute DES. At 5 years, TLF was 9.8%, TVMI 3.2%, TLR 4.6% and very late stent thrombosis 0.5%. Results of pre-specified subgroup analyses show 5-year TLF rates of 14.3% for diabetics and 13.4% for patients with chronic total occlusions. CONCLUSIONS: The RESOLUTE China Registry is the largest study of Asian patients treated with second-generation Resolute DES. Clinical outcomes illustrate a robust safety and efficacy profile of Resolute DES in a real-word Asian population, including favourable performance in complex patient subsets.
Authors: Pascal Vranckx; Donald E Cutlip; Roxana Mehran; Peter-Paul Kint; Sigmund Silber; Stephan Windecker; Patrick W Serruys Journal: EuroIntervention Date: 2010-02 Impact factor: 6.534
Authors: Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith Journal: Circulation Date: 2016-03-29 Impact factor: 29.690
Authors: Gregg W Stone; Alexandra J Lansky; Stuart J Pocock; Bernard J Gersh; George Dangas; S Chiu Wong; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Martin Möckel; Andrzej Ochala; Alison Kellock; Helen Parise; Roxana Mehran Journal: N Engl J Med Date: 2009-05-07 Impact factor: 91.245
Authors: Liefke C van der Heijden; Marlies M Kok; Peter W Danse; Alexander R Schramm; Marc Hartmann; Marije M Löwik; Gerard C M Linssen; Martin G Stoel; Carine J M Doggen; Clemens von Birgelen Journal: Am Heart J Date: 2016-03-17 Impact factor: 4.749
Authors: Manel Sabate; Angel Cequier; Andrés Iñiguez; Antonio Serra; Rosana Hernandez-Antolin; Vicente Mainar; Marco Valgimigli; Maurizio Tespili; Pieter den Heijer; Armando Bethencourt; Nicolás Vazquez; Joan Antoni Gómez-Hospital; José Antonio Baz; Victoria Martin-Yuste; Robert-Jan van Geuns; Fernando Alfonso; Pascual Bordes; Matteo Tebaldi; Monica Masotti; Antonio Silvestro; Bianca Backx; Salvatore Brugaletta; Gerrit Anne van Es; Patrick W Serruys Journal: Lancet Date: 2012-09-03 Impact factor: 79.321